Showing 1171-1180 of 9359 results for "".
- Sandoz Completes Acquisition of Fougera Pharmaceuticalshttps://practicaldermatology.com/news/20120727-sandoz_completes_acquisition_of_fougera_pharmaceuticals/2459760/Sandoz has completed its USD $1.525 billion acquisition of specialty dermatology company Fougera Pharmaceuticals. Combined with Sandoz's existing generic dermatology franchise, this acquisition positions Sandoz as the new #1 in generic dermatology medicines both globally and in the US. Fougera has …
- More Than 1,000 Ulthera Systems Sold Worldwidehttps://practicaldermatology.com/news/20120725-more_than_1000_ulthera_systems_sold_worldwide/2459764/Ulthera, Inc. has sold more than 1,000 Ulthera Systems globally, with more than 100,000 treatments performed using the System. Ultherapy is a non-invasive face and neck treatment to help lift and tighten. In the first half of 2012, the company reports that expansion into Latin America as well as fu…
- Ellman International Acquires Four Low-cost Lasers from Sandstonehttps://practicaldermatology.com/news/20120720-ellman_international_acquires_four_low-cost_lasers_from_sandstone/2459768/Ellman International, Inc. has acquired the assets of Sandstone Medical Technologies, LLC., a recognized leader in the aesthetic laser and IPL technology field. Sandstone's high quality laser and IPL portfolio offers four multifunctional systems, all priced under $50,000. The transaction significa…
- Suneva to Acquire Worldwide Rights to Refissa(R)https://practicaldermatology.com/news/20120604-suneva_to_acquire_worldwide_rights_to_refissar/2459789/Suneva Medical , a privately-held aesthetics company, will acquire worldwide rights to Refissa® and its marketed generic equivalent from Spear Pharmaceuticals. The portfolio contains the only tretinoin creams with a .05% strength, emollient base and broad indication for fine facial lines, hyperpig…
- Merz Realignment Focuses on Synergieshttps://practicaldermatology.com/news/20120518-merz_realignment_focuses_on_synergies/2459796/Merz is realigning and integrating its core businesses in the United States and Canada into one organization, with a single leadership team, the company announced. According to Merz, "the newly aligned structure is designed to strengthen the company's growth potential and to ensure Merz provides th…
- Promiseb Complete Launches for Seborrheic Dermatitishttps://practicaldermatology.com/news/20120425-promiseb_complete_launches_for_seborrheic_dermatitis/2459814/Promiseb Complete, a new regimen for patients with seborrheic dermatitis (SD), is now available from Promius Pharma, LLC, an affiliate of Dr. Reddy's Laboratories,. The line features Promiseb Topical Cream, a non-steroidal, prescription cream for the treatment of SD, and a companion product called …
- FDA Seeks More Information on Pliaglishttps://practicaldermatology.com/news/20120419-fda_seeks_more_information_on_pliaglis/2459818/FDA's Complete Response Letter to Galderma Laboratories LP outlines additional information the FDA requires before it will approve the sNDA for Pliaglis, developer Nuvo Research, Inc. reports. The response is to the supplemental New Drug Application (sNDA) for the lidocaine and tetracaine 7%/7% top…
- Amgen, Pfizer Will No Longer Co-Market Enbrelhttps://practicaldermatology.com/news/20120419-amgen_pfizer_will_no_longer_co-market_enbrel/2459819/Amgen and Pfizer will end co-promotion of Enbrel (etanercept) in North America this summer, the companies tell the Wall Street Journal. Amgen will assume full marketing responsibilities in the US, effective July 23.
- Merz Clarifies Status of Xeomin, Appoints William (Bill) Humphries CEOhttps://practicaldermatology.com/news/20120314-merz_clarifies_status_of_xeomin_appoints_new_ceo/2459845/Following a hearing in US District Court yesterday, Merz, Inc. is clarifying the availability of Xeomin and has appointed William (Bill) D. Humphries as CEO of Merz Inc., effective March 15. Merz Pharmaceuticals, LLC will continue to sell Xeomin for therapeutic uses in the US, following the ruling…
- Xeomin Injunction Stands; Another Hearing Scheduled for Tomorrowhttps://practicaldermatology.com/news/20120312-xeomin_injunction_stands_another_hearing_scheduled_for_tomorrow/2459848/Handing down his order as promised on Friday, US District Court Judge Andrew J. Guilford imposed a 10-month injunction barring Merz from selling or soliciting purchases of Xeomin®, in the US facial aesthetics market for 10 months. However, Judge Guilford called for another hearing on the case, orig…